These studies suggested CD133+ colon cancer cells from primary or metastatic tumors were equivalently resistant to oxaliplatin or Fas induced apoptosis, but this was reversed by inhibition of Fap1. This evidence concerns the gene PROM1 and colonic neoplasm.